Latest Updates
-
Independence Day 2026: Before Har Ghar Tiranga, Flying Your Flag Was Illegal -
Independence Day 2026: Is India Celebrating Its 79th Or 80th Year Of Freedom? -
Childhood Obesity: Myths vs. Facts — What An Endocrinologist Wants Every Parent To Know -
The New Wellness Souvenir: Why Travellers Are Returning Home With Healthy Habits Instead of Handicrafts -
Shravan 2026: These 5 Zodiac Signs May Get Lord Shiva's Special Blessings This Year -
Anupama Parameswaran Talks About Love, Control, and Finally Walking Away -
Migraine or Brain Tumour? The Headache Symptoms Doctors Say Not to Ignore -
OTT Releases This Week (10 To 17 August): What To Stream On Netflix, Prime, JioHotstar, Zee5 And SonyLIV -
Throwback Thursday: On Sridevi’s 63rd Birth Anniversary, Movies That Made Her Bollywood’s First Lady Superstar -
Why Your Skincare Might Be Silently Damaging Your Skin's pH Balance
Anti-Nausea Drug May Treat Sleep Apnoea
A drug used to treat nausea and vomiting in chemotherapy patients can significantly help people suffering from sleep apnoea, new research has revealed.
A drug used to treat nausea and vomiting in chemotherapy patients can significantly help people suffering from sleep apnoea, new research has revealed.
Obstructive sleep apnoea is a condition where breathing is briefly but repeatedly interrupted during sleep. It occurs when the throat muscles fail to keep the airway open during sleep despite efforts to breathe.

Researchers from the University of Illinois at Chicago (UIC), had in a previous study, found that dronabinol -- a cannabinoid agonist -- held significant potential for treating sleep apnoea.
While a cannabinoid is any of a group of closely related compounds which include cannabinol and the active constituents of cannabis, an agonist is a substance which initiates a physiological response when combined with a receptor.
The new study showed that "six weeks of treatment by the highest dose of dronabinol (10 milligrams) was associated with a lower frequency of apnoeas or hypopnoeas during sleep, decreased subjective sleepiness and greater overall treatment satisfaction", said David Carley, Professor at UIC.
Sleep-related breathing disorders, especially obstructive sleep apnoea, pose significant health problems. Individuals suffering from sleep apnoea have an increased risk for coronary heart disease, stroke, high blood pressure and Type 2 diabetes.

In the study, presented at the SLEEP 2017 annual meeting in Boston, the participants received the drug once daily before bed for six weeks.
"At the present time, there are no approved drug treatments for sleep apnoea and there remains an important unmet need for fully effective and acceptable treatments of the disorder," Carley said.
"By providing a path towards the first viable obstructive sleep apnoea drug, our studies could have a major impact on clinical practice," he added.
With Inputs From IANS
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications